. 2014 Aug 4;29(5):470–482. doi: 10.1002/hup.2424

Table 3.

Mean change from baseline to weeks 8 and 12 (full-analysis set): difference between vortioxetine and agomelatine (±SE)

	MMRM		ANCOVA, LOCF
Efficacy variable	Week 8	Week 12	Week 8	Week 12
Primary efficacy variable
MADRS total score	−2.2 ± 0.7^**^a	−2.0 ± 0.7^**	−3.1 ± 0.8^***	−3.5 ± 0.8^***
Secondary efficacy variables
Clinician-rated assessments
HAM-A total score	−1.9 ± 0.6^***	−1.9 ± 0.6^***	−2.4 ± 0.6^***	−2.8 ± 0.7^***
CGI-S score	−0.3 ± 0.1^**	−0.3 ± 0.1^**	−0.4 ± 0.1^***	−0.4 ± 0.1^***
CGI-I score	−0.3 ± 0.1^**	−0.3 ± 0.1^**	−0.4 ± 0.1^***	−0.5 ± 0.1^***
Patient-reported outcomes
SDS total score	−2.2 ± 0.7^**	−1.8 ± 0.8^*	−2.7 ± 0.7^***	−2.8 ± 0.8^***
SDS family life subscale	−0.58 ± 0.22^**	−0.43 ± 0.22	−0.76 ± 0.22^***	−0.70 ± 0.23^**
SDS work subscale	−0.70 ± 0.25^**	−0.55 ± 0.26^*	−0.88 ± 0.25^***	−0.86 ± 0.26^**
SDS social life subscale	−0.66 ± 0.23^**	−0.55 ± 0.22^*	−0.77 ± 0.23^***	−0.76 ± 0.24^**
EQ-5D overall health state score (VAS)	5.0 ± 1.7^**	4.7 ± 1.9^*	6.2 ± 1.7^***	6.6 ± 1.9^***
WLQ global productivity index	−0.01 ± 0.01^*	−0.01 ± 0.01	−0.01 ± 0.01^*	−0.01 ± 0.01
DFFS total score	−2.9 ± 0.9^**	−2.5 ± 1.0^*	−2.9 ± 0.9^**	−3.0 ± 1.0^**

CGI-I, Clinical Global Impression—Improvement; CGI-S, Clinical Global Impression—Severity; DFFS, Depression and Family Functioning Scale; EQ-5D, EuroQol 5 Dimensions; HAM-A, Hamilton Anxiety Rating Scale; LOCF, last observation carried forward; MADRS, Montgomery–Åsberg Depression Rating Scale; MMRM, mixed model for repeated measurements; SDS, Sheehan Disability Scale; VAS, visual analogue scale; WLQ, work limitation questionnaire; ANCOVA, analysis of covariance.

Primary efficacy analysis.

Absolute value.

^*p < 0.05 versus agomelatine.

^**

^*^*p < 0.01 versus agomelatine.

^***

^*^*^*p < 0.001 versus agomelatine, decreased values = improvement (except for EQ-5D where increased values = improvement).